Abdul Qadir

Abdul Qadir asked about the launch timelines for Semaglutide in India and other countries, including Brazil and Turkey, and whether the 12 million cartridge capacity has increased. He also questioned the impact of recent CRLs for Denosumab and Rituximab on overall biosimilar timelines and the planned launch timeline for Abatacept.

Answer

CEO Erez Israeli confirmed Semaglutide will launch in India on March 21st, with Canada expected between late February and May. Brazil and Turkey launches are anticipated around July. The 12 million pen capacity remains for the initial period, with additional capacity planned. He noted that the Rituximab delay (U.S.) is about a year plus, while Denosumab (U.S.) is delayed by at least six months. Abatacept IV product approval is expected by late calendar 2026, with sub-Q approval by January/February 2028.